Introduction: Safinamide is a recent antiparkinsonian drug that modulates both dopaminergic and glutamatergic systems with positive effects on motor and nonmotor symptoms of Parkinson’s disease (PD). Here, we aimed to describe the efficacy and safety of safinamide in the Italian PD patients in real-life conditions. Methods: We performed a sub-analysis of the Italian cohort of the SYNAPSES study, a multi-country, multi-center, retrospective-prospective cohort observational study, designed to investigate the use of safinamide in routine clinical practice. Patients received for the first time a treatment with safinamide and were followed up for 12 months. The analysis was conducted on the overall population and in subgroups of interest: i) patients > 75 years, ii) patients with relevant comorbidities and iii) patients affected by psychiatric symptoms. Results: Italy enrolled 616/1610 patients in 52 centers, accounting for 38% of the entire SYNAPSES cohort. Of the patients enrolled, 86.0% were evaluable at 12 months, with 23.3% being > 75 years, 42.4% with psychiatric conditions and 67.7% with relevant comorbidities. Safinamide was effective on motor symptoms and fluctuations as measured through the Unified PD rating scale III and IV scores, and on the total score, without safety issues in none of the subgroups considered. Conclusion: The SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients.

Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy / Bovenzi R.; Liguori C.; Canesi M.; D'Amelio M.; De Pandis M.F.; Marini C.; Monge A.; Padovani A.; Tessitore A.; Stefani A.; Zappia M; SYNAPSES Study Investigators Italian Group; Cortelli P.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - STAMPA. - 45:2(2024), pp. 573-583. [10.1007/s10072-023-07001-6]

Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy

Cortelli P.
Membro del Collaboration Group
2024

Abstract

Introduction: Safinamide is a recent antiparkinsonian drug that modulates both dopaminergic and glutamatergic systems with positive effects on motor and nonmotor symptoms of Parkinson’s disease (PD). Here, we aimed to describe the efficacy and safety of safinamide in the Italian PD patients in real-life conditions. Methods: We performed a sub-analysis of the Italian cohort of the SYNAPSES study, a multi-country, multi-center, retrospective-prospective cohort observational study, designed to investigate the use of safinamide in routine clinical practice. Patients received for the first time a treatment with safinamide and were followed up for 12 months. The analysis was conducted on the overall population and in subgroups of interest: i) patients > 75 years, ii) patients with relevant comorbidities and iii) patients affected by psychiatric symptoms. Results: Italy enrolled 616/1610 patients in 52 centers, accounting for 38% of the entire SYNAPSES cohort. Of the patients enrolled, 86.0% were evaluable at 12 months, with 23.3% being > 75 years, 42.4% with psychiatric conditions and 67.7% with relevant comorbidities. Safinamide was effective on motor symptoms and fluctuations as measured through the Unified PD rating scale III and IV scores, and on the total score, without safety issues in none of the subgroups considered. Conclusion: The SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients.
2024
Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy / Bovenzi R.; Liguori C.; Canesi M.; D'Amelio M.; De Pandis M.F.; Marini C.; Monge A.; Padovani A.; Tessitore A.; Stefani A.; Zappia M; SYNAPSES Study Investigators Italian Group; Cortelli P.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - STAMPA. - 45:2(2024), pp. 573-583. [10.1007/s10072-023-07001-6]
Bovenzi R.; Liguori C.; Canesi M.; D'Amelio M.; De Pandis M.F.; Marini C.; Monge A.; Padovani A.; Tessitore A.; Stefani A.; Zappia M; SYNAPSES Study Investigators Italian Group; Cortelli P.
File in questo prodotto:
File Dimensione Formato  
s10072-023-07001-6.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 652.5 kB
Formato Adobe PDF
652.5 kB Adobe PDF Visualizza/Apri
10072_2023_7001_MOESM1_ESM.docx

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 142.04 kB
Formato Microsoft Word XML
142.04 kB Microsoft Word XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/955133
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact